<DOC>
	<DOCNO>NCT02870140</DOCNO>
	<brief_summary>The primary objective study compare performance SUPRAFLEX XIENCE all-comers patient population symptomatic ischemic heart disease . The patient follow 3 year major clinical event .</brief_summary>
	<brief_title>Thin Strut Sirolimus-eluting Stent All Comers Population v Everolimus-eluting Stent</brief_title>
	<detailed_description>This prospective , randomize , 1:1 balance , control , single-blind , multi-center study compare clinical outcome 12 month SUPRAFLEX XIENCE `` Real world , comer '' patient population ( patient symptomatic coronary artery disease include patient chronic stable angina , silent ischemia , acute coronary syndrome , qualify percutaneous coronary intervention ) . The objective compare SUPRAFLEX SES XIENCE EES respect target lesion failure ( TLF ) 12 month non-inferiority trial `` real world '' patient population . All patient ( minimum ) contact 30 day , 6 month , 12 month post procedure ass clinical status adverse event . The 30 day 12 month clinic visit . All patient annual contact 3 year follow-up assess clinical status adverse event .</detailed_description>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>All comer '' patient : Male female patient 18 year old ; Presence one coronary artery stenoses 50 % native coronary artery saphenous venous arterial bypass conduit suitable coronary stent implantation . The vessel reference vessel diameter range ≥2.25 mm ≤4.5 mm ( limitation number treat lesion , vessel , lesion length ) ; All lesion patient must comply angiographic inclusion criterion . The patient ( legal guardian ) understand trial requirement treatment procedure provide write informed consent trialspecific test procedure perform . Patient willing comply protocolrequired evaluation . Known pregnancy breastfeed time randomization ; Known contraindication hypersensitivity sirolimus , everolimus , cobaltchromium , medication aspirin , heparin , bivalirudin , follow four medication : clopidogrel bisulfate , ticlopidine , prasugrel , ticagrelor ; Any PCI treatment within 6 month ( &lt; 6 month ) prior index procedure . Concurrent medical condition life expectancy le 12 month . The patient unwilling/ able return outpatient clinic 12 month followup . Currently participate another trial yet primary endpoint .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CAD</keyword>
	<keyword>ACS</keyword>
	<keyword>All comer</keyword>
	<keyword>PCI</keyword>
</DOC>